Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikeda, A.
Right arrow Articles by Izumi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikeda, A.
Right arrow Articles by Izumi, T.
(Chest. 1994;106:1740-1745.)
© 1994 American College of Chest Physicians

Oxitropium Bromide Improves Exercise Performance in Patients With COPD

Akihiko Ikeda MD1; Koichi Nishimura MD1; Hiroshi Koyama MD1; Naoharu Sugiura MD1; and Takateru Izumi MD, FCCP1

1 From the Chest Disease Research Institute, Kyoto University, Kyoto, Japan

Inhaled anticholinergics may be the first-line therapy for stable COPD. However, the effect of inhaled anti-cholinergic agents on exercise capacity is still controversial. Fourteen patients with stable COPD (age, 64.6 ± 5.9 years) completed a randomized, double-blind placebo-controlled crossover trial. All the patients were studied by symptom-limited progressive cycle ergometry before and 90 min after the inhalation of either oxitropium bromide, 800 µg, or an identical placebo. Spirometry was assessed before and after each exercise test. While FEV1, averaged 0.85 ± 0.34 L at 90 min after the inhalation of placebo, FEV1 was 1.01 ± 0.41 L at 90 min after the inhalation of oxitropium, 800 µg (significant from placebo, p<0.001). The maximal workload of 94.0 ± 25.8 W after oxitropium administration was significantly greater than the 87.6 ± 24.7 W measured after placebo (p<0.01). The maximal minute ventilation was 40.2 ± 12.3 L/min after oxitropium inhalation and 36.8 ± 10.5 after placebo inhalation (p<0.05). The differences in maximal oxygen consumption, maximal carbon dioxide production, and maximal heart rate between oxitropium and placebo inhalation also were statistically significant (p<0.05, p<0.05, and p <0.01, respectively). There was a significant correlation between the change in maximal workload and the change in FEV1 before and after inhalation (r=0.625, p<0.01). The inhalation of oxitropium bromide, 800 µg, can improve the exercise capacity of patients with stable COPD. It is suggested that the effect is due to the bronchodilation induced by this drug.

Key Words: anticholinergics • bronchodilator • chronic obstructive pulmonary disease • exercise capacity • oxitropium bromide • progressive cycle ergometry

Submitted on November 4, 1993
Accepted on May 17, 1994




This article has been cited by other articles:


Home page
 ChestHome page
J. J. W. Liesker, P. J. Wijkstra, N. H. T. Ten Hacken, G. H. Koeter, D. S. Postma, and H. A. M. Kerstjens
A Systematic Review of the Effects of Bronchodilators on Exercise Capacity in Patients With COPD
Chest, February 1, 2002; 121(2): 597 - 608.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. OGA, K. NISHIMURA, M. TSUKINO, T. HAJIRO, A. IKEDA, and T. IZUMI
The Effects of Oxitropium Bromide on Exercise Performance in Patients with Stable Chronic Obstructive Pulmonary Disease . A Comparison of Three Different Exercise Tests
Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 1897 - 1901.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American College of Chest Physicians.